Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

Simply Wall StSep 8 08:04 ET

Sangamo Therapeutics Analyst Ratings

BenzingaAug 22 09:02 ET · Ratings

H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsAug 22 06:33 ET · Ratings

Earnings Update: Here's Why Analysts Just Lifted Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target To US$3.80

Simply Wall StAug 9 06:16 ET

Q2 2024 Sangamo Therapeutics Inc Earnings Call

Yahoo FinanceAug 7 13:24 ET

Earnings Call: Sangamo Therapeutics Extends Cash Runway Into 2025

InvestingAug 7 11:56 ET